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Hligh-close insuilin treatineit (2 U Protamimine-zinceinsulin/10() g per day) resulted in normogiveyemia, 11n1o11mal] x'eight gainlt, miiild hyperinstilinemia, and Ietutlirn of glucagon levels toward l)ase line. The low-dose (1 U protamii ne-zinic-ilnstllin!10()() g per day) insulin-treated diabetic groip demonstrated chemical chnliages intermediate between the uintreatedl and the high-dose inisuiliti-trea.tecl animaltls.
In liver plasmiia membranes froum the untreated diabetic ratts, specific binding of' 1251-gluagon was increased by 95%. Analysis of' binding data suiggested( that thle chlianges in glucagon binding, were a conise-(qetciice of' alterations in binding cap(acity rather tlhan chalianges in binding affinity. Furtiherlmiore, in the iiitreateld dlial)etic rats, Iboth basal and gliicagoni (2 gUM)-stimulated adlenvlate cv-clase activity were twNofold higher thalnt in c-onitrols. In the higih-dose insulin-treated dlial)etic r-ats, glucagon billnding aicl( basal and gIlucagon-stimulated adcenvlate eve(ase Iactiv imm-nediately before use in a citric acid buffer adjusted to pH 4.5 and 0.2 ml of soltution was injected. Control rats received the dilueint only. The streptozotociin-treated rats developed glycosuria, polvdipsia, and hyperglycemia within 48 h after injection. On day 3 after streptozotociin iinjection, plasmiia glucose was measured, and only those rats with plasma glucose of 300 mg/100 ml or higher were included in the study. Diabetic rats were divided into three groups: (a) untreated diabetics; (b) high-dose insulin treatnmenit group; and (c) low-dose insulin treatment group. The high-dose and lowdose insulin treatmenit groups received, respectively, 2 U anid 1 U of Protamine-ziiuc-insulini (PZI) per 100 g body wt at 9 a.m. daily for 7 days beginninig 3 days after the administration of streptozotocin. The dose ofinsulin was chosen on the basis ofa pilot study which involved measurement of plasma glucose, urine sugar, and body weight twice daily on various Protamine-zinc-insulin (lose regimens. The insulin-treated rats were sacrificed 20-24 h after their last insulin dose, 7 days after institution of insulinl treatment (10 days after streptozotocin). The untreated animals were sacrificed 10 days after streptozotocin administration. Livers were quickly removed and blood was obtained by aortic punctutre for measuremenit of plasma glucose, insulin, and glucagon levels.
Preparationt of liver plasma membrantes. After removal, livers were quickly minced in 0.25 NI ice-cold sucrose and homogenized in 0.001 MI NaHCO3 solution in a Dounce homogenizer (Kontes Co., Vineland, N. J.) at 4°C. Partially purified plasma membranes were prepared by the method of Neville (7) as modified by Pohl et al. (8) . The preparation se(quenice was rigidly followed for membranes of all groups of rats. The specific activity of the plasma membrane marker enzyme, 5'-nucleotidase, was measured by the method of Avruch and Wallach (9) , and the microsomal marker enzNyme, glucose-6-phosphatase, was nmeasured bv the m-ethod of Swanson (10 (17) as described earlier (6) . The specific binding of 1251-insulin was calculated by subtracting nonspecific binding (125I-insulin bound in the presence of 1,OOq ng/ml of unlabeled insulin) from the total 1251-insulin binding (1251-insulin bound in the absence of unlabeled insulin). Insulin binding data were analyzed by Scatchard analysis (18) and the "average affinity profile" method (19) .
Reagents. Crystalline porcine glucagon and crystalline porcine insulin were a gift from Eli Lilly and Company (Indianapolis, Ind.). Carrier-free I251-Na was obtained from New England Nuclear (Boston, Mass.). Cellulose powder was obtained from Blood and plasma measurements. Plasma immunoreactive insulin and immunoreactive glucagon (using Unger antibody 30K) were determined as described previously (20) . Glucose was measured by the glucose oxidase technique (21) .
RESULTS
Body weight, plasma glucose, insulin, and glucagon (Table I) . During the course of the study, the untreated diabetic rats lost 18% oftheir body weight. In contrast, diabetic animals treated with the low-dose insulin regimen maintained their body weight, whereas those treated with high-dose insulin gained approximately the same weight as the control rats. Plasma glucose levels in the untreated and the low-dose insulin-treated diabetic animals were, respectively, four to fivefold and twofold greater than in the control rats, whereas high-dose insulin treatment resulted in normalization of the plasma glucose. As expected, the plasma insulin concentration in untreated diabetic animals was reduced by 67% as compared with controls.
In the diabetic animals treated with the low-dose insulin regimen, plasma insulin levels rose 75% above the concentration in the untreated group, but were still 40% below the normal controls. In the diabetic rats treated with the high-dose insulin regimen, plasma insulin levels were somewhat higher than in control animals. As expected (22) , plasma glucagon levels were threefold higher in untreated diabetic animals as compared with controls. The hyperglucagonemia in the diabetic animals was reversed by insulin treatment in a dose-dependent manner (Table I ). In the low-dose insulin group, plasma glucagon was reduced by 45% as compared to the untreated diabetics, whereas in the high-dose insulin group plasma glucagon fell by 60%. Hepatic plasma membrane purification. Table II summarizes the data on the membrane protein yield and the marker enzyme activity in liver membranes from control and diabetic rats. It is evident that the yield of membrane protein was identical in all four groups of animals. The untreated diabetic rats had significantly lower 5'-nucleotidase activity than control rats (P < 0.01). This finding is in keeping with that reported by other workers (23, 24) . Furthermore, both in the low-dose and in the high-dose insulin-treated groups 5'-nucleotidase activity increased to levels that were not significantly different from that of control rats. More importantly, as shown in Table II , purification of 5'-nucleotidase was identical in all four groups. With respect to glucose-6-phosphatase activity, plasma membranes from the untreated diabetic animals had significantly higher glucose-6-phosphatase activity compared with controls. Other workers have reported similar findings (23, 24) . It is of note that in all four groups of animals the specific activity of the plasma membrane marker enzyme, 5'-nucleotidase was increased 18-to 20-fold in partially purified liver membranes over that in the homogenate, whereas the specific activity of the microsomal enzyme, glucose-6-phosphatase in the liver plasma membrane preparation was less than that of the whole homogenate.
Effect of diabetes on glucagon binding and adenylate cyclase activity (Table III) . Specific binding of 125I-glucagon was studied in the control rats and in the untreated and insulin-treated diabetic rats. Glucagon binding was found to be linear over a range of membrane protein concentrations of 0.025 -1.4 mg/ml. In the control rats the specific binding of 1251-glucagon iii this study was in the same range as that reported by Rodbell et al. (15) . Glucagon binding in the untreated diabetic rats was 95% higher than in control rats (P < 0.001, Table III ). In the low-dose insulin-treated diabetic animals, glucagon binding fell by 30% as compared to the untreated diabetic rats (P < 0.01), but was still 35% higher than in control animals (P < 0.01).
In the high-dose insulin-treated diabetic group, the glucagon binding fell to values not significantly different from control rats (Table III) . In contrast to the specific binding of _25I-glucagon, the nonspecific binding of labeled glucagon was identical in the control (1.5%), in the untreated diabetics (1.6%), and in the insulin-treated diabetic rats (low dose 1.4%, high dose 1.8%).
The finding ofincreased glucagon binding in diabetic rats led us to investigate the adenylate cyclase activity in liver membranes from these rats because activation of adenylate cyclase is the next well-recognized step in the interaction between glucagon and its target organs. Both basal and stimulated adenylate cyclase activity were measured in the liver plasma membranes from each group of rats. As shown in Table III , in the untreated diabetic animals basal adenylate cyclase was 90% higher than in control rats (P < 0.001). In the low-dose insulin-treated rats, basal adenylate cyclase activity was 25% lower than in the untreated diabetic group (P < 0.05) but was still 38% higher than in the control rats (P < 0.05). In the high-dose inisulin-treated diabetic rats, basal adenylate cyclase was the same as that in control animals. Similar changes were observed in glucagon-stimulated adenylate cyclase activity. In the untreated diabetic animilals, glucagon-stimulated adenylate cyclase activity was 100% higher than in control animals (P < 0.001). The high-dose insulinitreated diabetic rats showed values comparable to controls, whereas in the low-dose group the response was intermediate between the values in control rats and untreated diabetic rats. The absolute increment above basal in adenylate cyclase activity induced by gltucagon was 4.15±+0.24 in control rats as compared with 8.36±0.90 in the uintreated diabetic rats (P < 0.001) and 6.12±0.62 in the low-dose insulin-treated group (P < 0.05 vs. controls or untreated diabetes) and 4.51±0.30 in the high-dose insulin-treated diabetic animals (P > 0.5 vs. controls). When 10 ,uM of epinephrine was added to liver membranes from control rats, adenylate cyclase activity was stinmuilated to a significantly lesser extent than by the addition of 2 ,uM of glucagon. This observation is similar to that reported by other workers (25) . As in the case of glucagon, epinephrine-stimulated adenylate cyclase was significantly higher in untreated diabetic rats thani in control animals (P < 0.01). However, epinephriniestimulated adenylate cvclase activity was fuilly nornmalized by low-dose as well as high-dose instulin treatment of diabetic animals. In conitrast to the effects of glucagon and epinephrine, the incremlent in adenylate cyclase activity induced by sodium fluoride in controls (2.60±)0.21) was not significantly different from that observed in the untreated diabetic rats (2.91+(0.22) or the insulin-treated diabetic animals (low dose 2.75+0.30, high dose 2.80±0.28).
In Fig. 1 , the effects of varying concenitrationis of' glucagon on the binding of '25I-glucagon and on the activation of adleniylate cyclase are compared. In the control as well as in the diabetic rats (Fig. 1) , saturation of binding sites or activation of adenylate cyclase occurred in the range of 50-75 nM of glucagon. As shown in Fig. 1 Fig. A and B each point is the mean of 16 (controls), 18 (uintreated diabetics), 8 (low-dose insulin-treated diabetics), and 12 (high-dose insulin-treated diabetics) individual experimiienits in the various groups.
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V. Sornan atnd P. Felig diabetic group (P < 0.05), but was still significanitly higher than in control animals (P < 0.05; Fig. 1 ). The rainge of concentrations over which labeled glucagon showed aIn increase in binding was similar to that found for activation of adenylate cyclase in all four groups of animals ( Fig. 1) . The concentration of glucagon giving half-maximal binding or activation of adenylate cyclase was betweeni 3 and 4 nM in all four groups of rats. Degradation of gluicagon by liver membratnes. To examine the possibility that decreased glucagon degradation by liver membranes from diabetic rats may account for increased glucagon binding by these membranes, the glucagon degradation activity was studied. Table IV shows the degradation of 1251_ gluicagon by liver membranies from control and diabetic rats. Gluicagon degradation activity was found to be linear over a membrane protein concentration of 0.05-2.5 mg/ml of incubation medium. Liver membranes fromi control and from untreated and insulintreated diabetic rats inactivated glucagon to the same extenit at a membrane protein concentration of 0.2 imng/iml.
Effects ofdiabetes on instulin binding. As expected (24) , the specific binding of 1251-irisulin in the untreated diabetic animals was 40% higher than in control rats (P < 0.01; Table V ). In the low-dose inisulin-treated diabetic animals, insulin binding was not significantly different from that of control rats, whereas in the high-dose insulin treatment group insulin binding was 30% lower than in control rats (P < 0.05). Analysis ofthe insulin binding data by Scatchard analysis (18) and average affinity profile (19 ; Table V) revealed that these differences in insulin binding between different animal groups were mainly a result of a change in the insulin binding capacity rather than to a change in binding affinity. 
DISCUSSION
The role of glucagon in fuel homeostasis in normiial and diabetic man has received increasinig attention in recent years (26, 27) . Although the essentiality of' glucagon in the pathogenesis of diabetes has been questioned (28), hypersensitivity to the hyperglycemic action of glucagon has been clearly demonstrated in instulin-deprived diabetes (2, 3) . Thuis, the glycemic response to hyperglucagonemi-ia was 5-15 times greater in insuilin-withdrawn diabetics than in normal subjects (2) . More recent studies comparing painereatectonmized man and juvenile-onset diabetics indicate that endogenous hyperglucagonemia worsens the hyperglycemia and ketonemia that accompany insulini deficiency (3) . Augmented sensitivity to the hyperglycemic effects of glucagon has also been reported in uremics (29) . In a previous study, increased glucagon binding to liver membranes was demonstrated as the cellular mechanism of glucagon hypersensitivity in uremia (6) .
The current data suggest that a similar mechanismn is operative in insulin-deficient diabetes.
In the present study, the untreated diabetic animals exhibited hyperglycemia, weight loss, hypoinsulinemia, and hyperglucagonemia. High-dose insulin treatment of these animals resulted in iiormoglycemia, normal weight gain, mild hyperinsulinemia, and return of glucagon levels toward base line. The low-dose insulin-treated group demonstrated changes in each of these parameters which were intermediate between the untreated diabetics and the high-dose insulintreated diabetic animals.
The findings with regard to recovery of plasma membrane protein and marker enzyme activities indicate that there were no significant differences in the membrane purification procedure in the four groups of animals that comprise the present study. As compared to the homogenate, the partially purified plasma membranes from all four groups of rats were enriched 18-20 times in the membrane marker enzyme, 5'-nucleotidase. As indicated by the relative activities of the microsomal enzyme glucose-6-phosphatase in the homogenate and membrane fractions, there was minimal contamination of membranes in each of the experimental groups (Table II) . These findings thus indicate that changes in glucagon binding observed in the diabetic rats cannot be ascribed to a systematic effect ofthe diabetic state on the membrane purification procedure. As previously reported (23, 24) , plasma membranes from the untreated diabetic rats had significantly decreased 5'-nucleotidase activity, whereas glucose-6-phosphatase activity was somewhat increased in diabetic rats. Of interest is our observation that insulin treatment resulted in normalization of 5'-nucleotidase activity in diabetic membranes, suggesting that insulin is an important regulator of this membrane enzyme.
The specific binding of 1251-glucagon was approximately twofold higher in the untreated diabetic rats as compared to the control rats (Table III) . Insulin treatment of diabetic rats resulted in normalization of glucagon binding in a dose-dependenit manner. As shown in Fig. 1 (Fig. 1) . These data suggest that increased glucagon binding in the tuntreated diabetic rats and in the low-dose insulintreated diabetic rats is a result of an increase in the number of binding sites rather than a consequence of a change in binding affin-ity. It should be noted that Davidson and Kaplani (24) in their study of insulin binding in streptozotocin-treated diabetic rats reported that glucagon binding in diabetic anirnals was not significantly different from that of controls. However, the technique employed by those authors involved the repeated assay of a single pool of membranes obtained from each of two groups (normal and diabetic) rather than separate assays of membranes from each of 16-18 rats in the diabetic and control groups (Table III) .
The finding of increased glucagon binding in diabetic animals led us to investigate the adenylate cyclase activity in these animals. We found that the basal adenylate cyclase activity in the untreated diabetic animals was about twofold higher than in control rats and that insulin treatment led to normalization of basal cyclase in a dose-dependent manner (Table III) . Of even greater interest are our findings related to the effect of glucagon on adenylate cyclase activity. Glucagon-stimulated adenylate cyclase activity was significantly higher in the untreated diabetic animals as compared with controls. A similar augmentation in epinephrine-stimulated adenylate cyclase activity was observed in the diabetic animals and is in keeping with the increased sensitivity to the hyperketonemic and hyperglycemic effects of epinephrine in insulindeprived diabetics (30) . Insulin treatment of diabetic animals resulted in reversal of the increased glucagonstimulated and epinephrine-stimulated adenylate cyclase activity in a manner similar to the changes observed in glucagon binding and in basal adenylate cyclase activity. In contrast to the glucagon-stimulated and epinephrine-stimulated adenylate cyclase activity, sodium fluoride-stimulated adenylate cyclase activity was similar in all four groups of animals. These findings indicate that the augmented response to glucagon and epinephrine in diabetic animals is not a consequence of a nonspecific increase in responsiveness of this system to all stimuli. The close correlation between changes in glucagon binding (Fig. 1 A) and glucagon-stimulated adenylate cyclase activity (Fig. 1 B) observed in the present study is of particular interest because alterations in hormone binding and in hormone action are not always parallel (31).
Our observations regarding adenylate cyclase activity are supported by the studies of Hepp (32) in mouse liver. In that study basal and glucagon-stimulated adenylate cyclase activity were found to be significantly higher in livers from streptozotocin-treated mice and, in a small number of animals studied, insulin treatment led to the reversal of the glucagon effect toward control values. However, our observations regarding basal and glucagon-stimulated adenylate cyclase activity are at variance with the report of Pilkis et al. (33) . Those workers observed that basal and maximal glucagonstimulated adenylate cyclase activity were no different in streptozotocin diabetic rats and control rats. One major difference between our studies and that of Pilkis et al. (33) that may possibly account for the different results is the fact that Pilkis et al. appear to have used fully purified liver membranes in their experiments, whereas all our studies were done with partially purified plasma membranes. The studies of Pohl et al. (8) clearly indicate that a significant amount of adenylate cyclase activity is lost during the final purificationi step of preparing plasma membranes. The lower protein yield and lower basal adenylate cyclase activity in the studies of Pilkis et al. (33) as compared to the present report support this notion. Furthermore, the degree of diabetes in their animals (blood sugar -300 mg/100 ml) appears to be milder as compared with the diabetic animals used in the present study.
To examine the possibility that increased glucagon binding and adenylate cyclase activity in diabetic membranes may be a consequence of a significant decrease in glucagon degradation activity in these membranes, we studied the glucagon degradation process in membranes from all groups of animals. As is evident from data in Table IV , the glucagon degrading activity as measured by three different parameters was identical in all four groups. Thus, the observed changes in glucagon binding and adenylate cyclase activity in different groups do not appear to be related to alterations in the glucagon degradation process by these membranes.
The mechanism(s) of increased glucagon binding and augmented adenylate cyclase activity in diabetic animals remains to be established. Both decreased and increased binding of glucagon have been reported in association with hyperglucagonemia. Thus, in starvation (34) and in association with continuous administration of exogenous glucagon,1 a decrease in glucagon 1 Soman, V., and P. Felig. Unpublished observations. binding is observed. In contrast, the hyperglucagonenmia of uremia is associated with increased glucagon binding (6) . The finding in the present study that in diabetic rats insulin treatment results in the reversal of increased glucagon binding and of increased basal and glucagon-stimulated adenylate cyclase activity raises the possibility that insulin either directly or through its effect on the plasma glucagon concentration regulates the glucagon receptor. In this regard the studies indicating estrogen stimulation of prolactin receptors (35) and induction of luteinizing hormone receptors in the granulosa cells of the ovary by follicle-stimulating hormone (36) are of great interest. Regardless of the mechanism involved, increased glucagon binding, coupled with augmented basal and glucagon-stimulated adenylate cyclase activity in insulin-deprived diabetic rats, may provide a cellular basis for the increased glycemic and ketonemic response to glucagon in insulin-deprived diabetics (2, 3) .
In addition to the changes in glucagon binding and adenylate cyclase activity, our findings demonstrated an increase in insulin binding by liver membranes from diabetic rats which was normalized by low-dose insulin treatment despite the fact that mild hyperglycemia persisted. These observations confirm previous work by Davidson and Kaplan (24) . In addition, in the high-dose insulin-treated group, peripheral hyperinsulinemia was achieved (Table I ) and insulin binding fell by 30% below normal control levels ( Table V) . The current data thus provide further confirmation for the conclusion that insulin binding is inversely related to the ambient insulin concentration and that this hormone may modulate its own receptor (37) .
